UID:
almahu_9949709363402882
Umfang:
1 online resource (492 pages)
Ausgabe:
First edition.
ISBN:
0-443-15413-9
Anmerkung:
Front Cover -- Curcumin-Based Nanomedicines as Cancer Therapeutics -- Copyright Page -- Contents -- List of contributors -- A. Curcumin: Introduction, structure, and physicochemical attributes -- 1 Curcumin: historical background, introduction, structure, and physicochemical attributes -- 1.1 Historical background -- 1.2 Characteristics -- 1.3 Components -- 1.4 Benefits, pharmacological effect, and potential therapeutic effect of turmeric and its major compound curcumin -- 1.4.1 Antiinflammation activity -- 1.4.2 Antioxidant activity -- 1.4.3 Protective effects on cardiovascular disease -- 1.4.4 Antidiabetic properties -- 1.4.5 Effect on the gastrointestinal tract -- 1.4.6 Effect on the skin -- 1.4.7 Neuroprotective effect -- 1.4.8 Hepatoprotective effect -- 1.4.9 Anticancer effect -- 1.4.10 Antimicrobial properties -- 1.5 Toxicity -- 1.6 Conclusion -- Conflict of interests -- References -- 2 Curcumin as a pharmaceutical leader -- 2.1 Introduction -- 2.2 Therapeutic activities of curcumin -- 2.2.1 Curcumin and neurological diseases -- 2.2.2 Curcumin and cardiovascular diseases -- 2.2.3 Curcumin and gastrointestinal disorders -- 2.2.4 Curcumin and hepatoprotective -- 2.2.5 Curcumin and respiratory disorders -- 2.2.6 Curcumin and cancer -- 2.2.7 Curcumin and diabetes mellitus -- 2.2.8 Curcumin and autoimmune diseases -- 2.2.9 Curcumin as a chelating agent -- 2.3 Conclusion -- Conflict of interests -- References -- 3 Chemical structure and molecular targets of curcumin for cancer therapy -- 3.1 Introduction -- 3.2 Chemistry of curcumin -- 3.3 Functionalities and synthesis of natural curcumin -- 3.4 Curcumin revamped to super curcumin -- 3.4.1 Curcumin-based pyrazole analogs -- 3.4.2 Bioisosteric-based curcumin analogs -- 3.4.3 Pyrimidine-based curcumin analogs -- 3.4.4 Furochromone carbaldehyde-based curcumin analogs.
,
3.4.5 Bioconjugate-based curcumin analogs -- 3.4.6 Electron-rich curcumin analogs -- 3.4.7 Carbonyl analogs of curcumin -- 3.4.8 Indole analogs of curcumin -- 3.4.9 Ester and acid analogs of curcumin -- 3.4.10 Coumarin analogs of curcumin -- 3.4.11 Hybrid analogs of curcumin -- 3.5 Curcumin as tumor suppressor and its molecular targets -- 3.6 Curcumin for cancer therapy -- 3.6.1 Breast cancer -- 3.6.2 Prostate cancer -- 3.6.3 Brain cancer -- 3.6.4 Leukemia -- 3.6.5 Lung cancer -- 3.6.6 Lymphoma -- 3.6.7 Multiple myeloma -- 3.6.8 Liver cancer -- 3.6.9 Gastric cancer -- 3.6.10 Colorectal cancer -- 3.6.11 Pancreatic cancer -- 3.6.12 Hepatic cancer -- 3.7 Conclusion and future perspective -- Acknowledgment -- References -- 4 Structural features of curcumin and its effects on cancer-related signaling pathways -- 4.1 Curcumin chemistry -- 4.2 Changes in a structurally modified curcumin's anticancer activity -- 4.3 Curcumin's function on CDK inhibitors and CDK/cyclin complexes -- 4.4 P53 pathway and curcumin interaction -- 4.5 Curcumin's targets in the cancer signaling pathway -- 4.6 Activation of Ras signaling by curcumin -- 4.7 Effect of curcumin in PI3K/AKT/mTOR signaling -- 4.8 Curcumin's effect on Wnt/β-catenin signaling pathway -- 4.9 Role of curcumin on transcription factors in cancer -- 4.10 Role of curcumin in NF-κB and AP-1 signaling pathway -- 4.11 Role of curcumin in STAT signaling -- 4.12 Conclusions -- References -- 5 An overview of cellular, molecular, and biological aspect(s) of curcumin in cancer -- Abbreviation -- 5.1 Introduction -- 5.2 Inducing apoptosis -- 5.2.1 Apoptosis-related protein modulation -- 5.2.2 Fas-FasL interaction -- 5.2.3 Reactive oxygen species generation -- 5.2.4 Other mechanisms -- 5.3 Tumor suppressor genes -- 5.3.1 P53 Tumor suppressor -- 5.3.2 Phosphatase and tensin homolog -- 5.3.3 RARβ -- 5.4 The survival pathways.
,
5.4.1 Nuclear factor-kappa B -- 5.4.2 The JAK/STAT signaling pathway -- 5.4.3 The Wnt/β-catenin signaling pathway -- 5.5 Angiogenesis -- 5.6 Metastasis -- 5.7 Conclusion -- References -- B. Smart drug delivery approaches for curcumin delivery in cancer therapy -- 6 Curcumin-drug conjugate-based drug delivery as cancer therapeutics -- 6.1 Introduction -- 6.2 Curcumin-drug conjugates in cancer therapy -- 6.2.1 Improving pharmacokinetics -- 6.2.1.1 Producing prodrugs -- 6.2.1.2 Producing self-assembled conjugates creating nanosized micelles -- 6.2.1.3 Producing conjugates for targeted delivery of curcumin -- 6.2.2 Improving pharmacodynamics -- 6.3 Conclusion -- References -- 7 Curcumin microcapsule-based drug delivery as cancer therapeutics -- 7.1 Introduction -- 7.2 Microcapsule-based drug delivery systems -- 7.3 Methods for microencapsulation -- 7.4 Coating materials -- 7.5 Characterization of curcumin-loaded microcapsules -- 7.6 Coacervation -- 7.7 Other preparation techniques -- 7.8 Codelivery of curcumin using microcapsules -- 7.9 Antitumor efficiency of curcumin microcapsules -- 7.10 Conclusion -- References -- C. Recent advances and regulatory aspects of gold nanoparticles -- 8 Nanoemulsion-based curcumin delivery systems as cancer therapeutics -- 8.1 Introduction -- 8.2 Nanoemulsions -- 8.3 Nanoemulsion structure -- 8.4 Preparation of nanoemulsions -- 8.5 Low-energy emulsification methods -- 8.5.1 Phase inversion emulsification method -- 8.5.2 The self-nanoemulsification method -- 8.6 High-energy emulsification methods -- 8.7 Physicochemical characteristics of nanoemulsions -- 8.8 Advantages of nanoemulsions as delivery systems -- 8.9 Nanoemulsions for delivery of curcumin -- 8.10 Parenteral curcumin nanoemulsions -- 8.11 Oral curcumin nanoemulsions -- 8.12 Curcumin nanoemulsions for cancer therapy.
,
8.13 Passive targeting of curcumin nanoemulsions -- 8.14 Active targeting of curcumin nanoemulsions -- 8.15 Curcumin coloaded nanoemulsions for cancer therapy -- 8.16 Curcumin nanoemulsions in clinical trial -- 8.17 Conclusion -- References -- 9 Micelle-based curcumin delivery systems as cancer therapeutics -- 9.1 Introduction -- 9.2 Lipid-based micelles -- 9.2.1 Traditional lipid-based micelles -- 9.2.2 Targeted lipid-based micelles -- 9.2.3 Stimuli-responsive lipid-based micelles -- 9.2.3.1 pH-sensitive lipid-based micelles -- 9.2.3.2 Reactive oxygen species-responsive lipid-based micelles -- 9.2.4 Chemoresistant lipid-based micelles -- 9.3 Polymeric micelles -- 9.3.1 Traditional polymeric micelles -- 9.3.2 Targeted micelles -- 9.3.3 Stimuli-responsive micelles -- 9.3.3.1 pH sensitive -- 9.3.3.2 Reactive oxygen species/Glutathione responsive micelles -- 9.3.3.3 Ultrasound responsive -- 9.3.3.4 Enzyme responsive -- 9.3.3.5 Dual responsive -- 9.3.4 Chemoresistant polymeric micelles (multidrug resistance) -- 9.4 Future insights -- References -- 10 Liposome-based curcumin delivery systems as cancer therapeutics -- 10.1 Introduction -- 10.2 Conventional liposomes -- 10.2.1 Skin cancer (melanoma) -- 10.2.2 Pancreatic cancer -- 10.2.3 Liver cancer -- 10.2.4 Colorectal cancer -- 10.2.5 Stomach cancer -- 10.2.6 Head and neck squamous carcinoma -- 10.2.7 Breast cancer -- 10.2.8 Endometrial carcinoma -- 10.2.9 Prostate cancer -- 10.2.10 Osteosarcoma -- 10.2.11 Lung cancer -- 10.3 Actively targeted liposome -- 10.3.1 Cervical cancer -- 10.3.2 Lung cancer -- 10.3.3 Breast cancer -- 10.3.4 Hepatocellular carcinoma -- 10.3.5 Acute myeloid leukemia -- 10.3.6 Skin cancer -- 10.3.7 Osteosarcoma -- 10.3.8 Pancreatic cancer -- 10.3.9 Prostate cancer -- 10.3.10 Brain tumors -- 10.4 Physical stimuli-responsive curcumin liposomal delivery systems -- 10.4.1 Skin cancer.
,
10.4.2 Pancreatic cancer -- 10.4.3 Breast cancer -- 10.4.4 Colon cancer -- 10.5 Microfluidic -- 10.6 Tissue engineering -- 10.7 Clinical studies -- 10.8 Future insights -- References -- 11 Inorganic nanoparticle-based curcumin delivery as cancer therapeutics -- 11.1 Introduction -- 11.1.1 Inorganic nanoparticles -- 11.2 Different types of inorganic nanoparticles -- 11.2.1 Metal oxide nanoparticle -- 11.2.1.1 TiO2 -- 11.2.1.2 ZnO -- 11.2.1.3 Cerium oxide -- 11.2.1.4 Superparamagnetic iron oxide nanoparticles -- 11.2.2 Mesoporous silica nanoparticles -- 11.2.3 Gold nanoparticles -- 11.2.4 Quantum dot nanoparticles -- 11.2.5 Upconversion nanoparticle -- 11.3 Conclusion -- References -- 12 PLGA nanoparticle-based curcumin delivery as cancer therapeutics -- 12.1 Introduction -- 12.2 Curcumin-PLGA nanoparticles in cancer therapy -- 12.3 Breast cancer -- 12.4 Ovarian cancer -- 12.5 Cervical cancer -- 12.6 Colorectal cancer -- 12.7 Prostate cancer -- 12.8 Liver cancer -- 12.9 Brain cancer -- 12.10 Other types of cancers -- 12.11 Combination therapy -- 12.11.1 Curcumin analogs for cancer treatment -- 12.12 Conclusion -- References -- 13 Polymersomes-based curcumin delivery as cancer therapeutics -- List of abbreviations -- 13.1 Introduction -- 13.2 Polymersomes as nanoformulations for curcumin delivery -- 13.3 Polymersomes for dual-drug delivery using responsiveness or surface functionalization -- 13.4 Final considerations -- Acknowledgments -- References -- D. Recent advances in nanocurcumin delivery in cancer therapy -- 14 Biopolymer-based formulations for curcumin delivery toward cancer management -- 14.1 Introduction -- 14.2 Curcumin bioavailability -- 14.3 Curcumin's absorption and stability -- 14.4 Utilizing nanotechnology to create derivatives of curcuma -- 14.5 Combination nanomedicine with curcumin -- 14.5.1 Colorectal cancer -- 14.5.2 Breast cancer.
,
14.5.3 Liver cancer.
Weitere Ausg.:
ISBN 0-443-15412-0
Sprache:
Englisch
